Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2009
11/03/2009US7611832 Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
11/03/2009US7611722 Reduced contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, which is particularly advantageous for delivering an ulcerative drug.
11/03/2009CA2449729C Prodrugs of gaba analogs, compositions and uses thereof
11/03/2009CA2448035C New pharmaceutical composition
11/03/2009CA2418961C Anti-il-12 antibodies, compositions, methods and uses
11/03/2009CA2415272C Improvements in and relating to the use of honey in dressings
11/03/2009CA2385477C Pca3 messenger rna species in benign and malignant prostate tissues
11/03/2009CA2353133C Treatment of disorders secondary to organic impairments
11/03/2009CA2324283C Pharmaceutical composition containing a statin and aspirin
10/2009
10/30/2009CA2629318A1 Clean hands, disinfectant container pad (germ protector)
10/29/2009WO2009131553A2 Methods of altering bone growth by administration of sost or wise antagonist or agonist
10/29/2009WO2009131200A1 Therapeutic agent for irritable bowel syndrome
10/29/2009WO2009131098A1 Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components
10/29/2009WO2009106549A3 Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
10/29/2009WO2009102465A3 Continuous cell programming devices
10/29/2009WO2009098072A3 Composition for the treatment of oxidative stress
10/29/2009WO2009083643A3 Composition for treating sterile inflammation
10/29/2009US20090270820 System and method for use of agent in combination with subatmospheric pressure tissue treatment
10/29/2009US20090270506 Crystalline structure of oxidosqualene synthase
10/29/2009US20090270464 Benzimidazole derivative and use as a II receptor antagonist
10/29/2009US20090270341 Product comprising a transduction inhibitor of heterotrimeric g protein signals combined with another anti-cancer agent for therapeutic use in the treatment of cancer
10/29/2009US20090270310 Process for the preparation of a nutrient formulation
10/29/2009US20090269365 Immunogenic vaccinia peptides and methods of using same
10/29/2009US20090269352 Antitumor agent comprising sulfonamide-containing heterocyclic compound combined with an angiogenesis inhibitor
10/29/2009US20090269337 Compositions and methods for treating diabetes
10/29/2009US20090269325 using non-anticoagulant sulfated polysaccharides (NASPs) e.g. pentosan polysulfate or heparins as procoagulants for treating bleeding disorder selected from a chronic or acute bleeding disorder, a congenital coagulation disorder caused by a blood factor deficiency, and an acquired coagulation disorder
10/29/2009US20090269321 Immune Function Modulating Agents
10/29/2009US20090269319 ARPE-19 as a Platform Cell Line for Encapsulated Cell-Based Delivery
10/29/2009US20090269285 Diagnostic And Therapeutic Epitope, And Transgenic Plant
10/29/2009DE102008019916A1 Use of proteasome inhibitors e.g. for the elimination of durable plasma cells, and for treating diseases that are associated with pathogenic antibodies, e.g. systemic lupus erythematosus, autoimmune hemolytic anemia and immune thrombopenia
10/28/2009EP2112234A2 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
10/28/2009EP2112222A1 Gene encoding guanine nucleotide exchange factor and gene product thereof
10/28/2009EP2112167A2 Humanized ANTI-ERBB2 antibodies and treatment with ANTI-ERBB2 antibodies
10/28/2009EP2111862A1 Pharmaceutical product for prevention and treatment of alzheimer's dementia
10/28/2009EP2111861A1 Compositions of phosphodiesterase type IV inhibitors
10/28/2009EP2111402A2 Aminopyrazole kinase inhibitors
10/28/2009EP2111262A2 1,3-dihydroimidazoles for treating cardiovascular disorders
10/28/2009EP1758469B1 Improvement of barrier integrity in hiv patients by use of fatty acids
10/28/2009EP1656122B1 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease
10/28/2009EP1503800B1 Treatment and prevention of tissue damage associated with increased c-reactive protein production
10/28/2009EP1408967B1 PHARMACEUTICAL COMPOSITIONS BASED ON Tiotropium, Ciclesonide AND a BETAMIMETIC AGENT FOR THE TREATMENT OF INFLAMMATORY AND/OR OBSTRUCTIVE RESPIRATORY TRACT DISEASES
10/28/2009EP1404323B1 Use of methylnaltrexone to treat immune suppression
10/28/2009EP1214057B1 Vascular coating composition
10/28/2009EP1150666B1 Gm-csf for the treatment of crohn's disease
10/28/2009EP1128731B1 Compositions of restricted cells capable of rapid growth which produce proliferation suppressive materials, and uses thereof
10/28/2009EP0983361B1 Bacterial pheromones and uses therefor
10/28/2009EP0915706B1 Screening methods for compounds useful in the regulation of body weight
10/28/2009CN101568362A Methods for treating depression
10/28/2009CN101568361A Use of nutritional compositions for preventing disorders
10/28/2009CN101568350A Lipidized interferon and uses thereof
10/28/2009CN101568341A Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
10/28/2009CN101568338A Novel therapeutic use for treating leukaemia
10/28/2009CN101565459A Streptococcus pneumoniae proteins and nucleic acid molecules
10/28/2009CN101565412A Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
10/28/2009CN101564571A Medical apparatus containing rapamycin analogue
10/28/2009CN101564536A Sustained and controlled release preparation for pharmaceutical composition for curing hypertension
10/28/2009CN101564383A Skin external used patch
10/28/2009CN100554966C A screening method
10/28/2009CN100553677C Drugs for treating vascular diseases
10/28/2009CN100553646C Use of probiotic lactic acid bacteria for balancing the skin's immune system
10/28/2009CN100553639C Boronic acid polyvalent salts for treating thrombosis
10/28/2009CN100553637C Hormone composition
10/28/2009CN100553635C Pharmaceutical composition containing amoxicillin, ambroxol and beta lactamase inhibitor and uses thereof
10/28/2009CN100553634C Epothilone derivatives for the treatment of multiple myeloma
10/27/2009US7608696 Immunoglobulin for use in diagnosis and prognosis of metastatic breast cancer and degenerative neural conditions; drug screening; immunotherapy and diagnostics; anticarcinogenic agents
10/27/2009US7608687 Releasable linkage and compositions containing same
10/27/2009US7608683 Human leukocyte antigen pan DR-binding peptides for use in the treatment of infections, inflammatory, autoimmune and cancer diseases; has heat shock protein that is capable of binding to MHC class II molecules
10/27/2009US7608640 Curative and preventive activity in the pathogenesis of thrombo-embolic and haemostatic diseases of arterial or venous origin
10/27/2009US7608637 Prevention and treatment of bone disorders with EP4 agonistfor compounds posessing prostaglandins structure
10/27/2009US7608634 Substituted pyrrolines as kinase inhibitors
10/27/2009US7608618 1-(2,2,2-trifluoroethanoyl)pyrrolidine-2-carboxylic acid [4-methoxy-3-(3-pyrazin-2-yl-ureido)phenyl]-amide; 4-Methoxy-N-(3-methylamino-propyl)-3-(3-pyrazin-2-yl-ureido)-benzamide; checkpoint kinase Chk1 inhibitor; chemosensitizing agents useful in the treatment of diseases related to DNA damage
10/27/2009US7608601 4′-Substituted nucleoside derivatives as inhibitors of HCV RNA replication
10/27/2009US7608585 Brain-derived neurotrophic factor (BDNF) and antioxidant Neu 2000 which is 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethylbenzylamino)benzoic acid; synergistic; neuroprotectant
10/27/2009US7608579 Lung volume reduction using glue compositions
10/27/2009US7608452 Polynucleotides encoding cytokine receptor zcytor19
10/27/2009US7608409 Screening assay using G-protein coupled receptor protein OT7T175
10/27/2009US7608284 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli
10/27/2009US7608281 Retinoic acid receptors (RAR); tissue engineering, cartilage formation; for treatment of cartilage degenerative disease, skeletal trauma; bone morphogenetic protein (BMP), osteogenic protein (OP)
10/27/2009US7608279 Stable oil in water emulsion containing deactivated immunogen such as Mycoplasma or circovirus with mineral and nonionic surfactant ; induce immunology response
10/27/2009US7608278 Less painful immunogenic composition of a hydrophobic protein; solubilizing hydrophobic protein with a zwitterionic detergent to make a composition that is then altered; meningitis or gonorrhea
10/27/2009US7608267 Fusion protein of two different cytokines, one capable of enhancing a nonspecific immune response, and the other capable of enhancing a specific immunity; fusion protein of Interleukin-2 (Il-2) and IL-7 for example; use in immunotherapy such as cancer vaccine
10/27/2009US7608257 Using a reovirus and chemotherapeutic agents to treat ras-activated neoplastic cells; proliferative disorders
10/27/2009US7608255 Replication-competent anti-cancer vectors
10/27/2009US7608245 Transmission and, or amplification of signal ; oral or enteric administering; dissolving; absorption by small inteestines; peptide yy; obesity therapy
10/27/2009CA2471565C Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
10/27/2009CA2454664C Cancer treatment with go6976 and its related compounds
10/27/2009CA2410488C Methods of treating hepatitis delta virus infection with .beta.-l-2' deoxy-nucleosides
10/27/2009CA2349529C Pge synthase and methods and means for modulating its activity
10/22/2009WO2009129187A2 Combination therapy for glaucoma
10/22/2009WO2009128523A1 Immunostimulating agent
10/22/2009WO2009128360A1 Therapeutic agent for diabetes
10/22/2009WO2009128273A1 Iontophoresis preparation for treating breast cancer and/or mastitis
10/22/2009WO2009128058A1 Psycho-pharmaceuticals
10/22/2009WO2009127825A1 Topical combinations comprising an antimycotic agent and an antiviral agent
10/22/2009WO2009127283A1 Use of a composition containing healing earth as an antacid
10/22/2009WO2009127251A1 Combinations comprising a renin inhibitor
10/22/2009WO2009127210A1 Vasodilating agents for the treatment of sleep attacks
10/22/2009WO2009093264A3 Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc.
10/22/2009WO2009087652A3 Pharmaceutical compositions, comprising calcitriol and calcium
10/22/2009WO2009082819A8 Novel lupane derivatives
1 ... 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 ... 1151